Arbutus Biopharma is a publicly-traded (NASDAQ:ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease. Source
No articles found.
Neopenda is a medical device startup creating solutions that give patients in low-...
Neopenda is a medical device startup creating s...
ENDRA Life Sciences' mission is to bring new capabilities to ultrasound and broade...
ENDRA Life Sciences' mission is to bring new ca...
Ligand is a biopharmaceutical company focused on developing or acquiring technolog...
Ligand is a biopharmaceutical company focused o...
Rhythm is a biopharmaceutical company dedicated to changing how rare genetic disor...
Rhythm is a biopharmaceutical company dedicated...
ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to ...
ImmunoGen is developing the next generation of ...
Aptinyx Inc. is a clinical-stage biopharmaceutical company discovering and develop...
Aptinyx Inc. is a clinical-stage biopharmaceuti...
Benitec is a biotechnology company developing a proprietary therapeutic technology...
Benitec is a biotechnology company developing a...
Join the National Investor Network and get the latest information with your interests in mind.